🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "major milestone" in the fight against drug-resistant strains of the pathogen, according to scientists.

An International Challenge

Gonorrhoea infections are increasing globally, with estimates suggesting in excess of 82 million new cases each year. Especially elevated rates are reported in the African continent and nations within the WHO's designated area, which includes Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune advancement in the reality of increasing worldwide cases, escalating drug resistance and the highly restricted treatment choices currently available.”

Health officials are particularly alarmed about the rise in treatment-resistant strains. The WHO has designated it as a "high-priority threat". Ongoing monitoring showed that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Gain Approval

Zoliflodacin, also known as Nuzolvence, was authorized by the US FDA in mid-December for combating gonorrhoea. This disease can lead to significant complications, including infertility. Experts believe that targeted use of this new drug will help hinder the development of resistance.

Gepotidacin, developed by the drugmaker GSK, was also approved in concurrent days. This treatment, which is employed against urinary tract infections, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin was the result of a new, not-for-profit approach for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to see it through.

“This approval marks a huge turning point in the management of superbug gonorrhoea, which previously has been outpacing our drug pipeline.”

Clinical Trial Results and Global Access

According to data released by a major medical journal, zoliflodacin eradicated more than 90% of genital gonorrhoea infections. This puts it on an comparable level with the existing first-line therapy, which involves two antibiotics. The study included over 900 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the ability to license and sell the drug in numerous developing nations.

Doctors on the front lines have shared optimism. The availability of a easy-to-administer therapy of this kind is hailed as a "critical tool" for public health efforts. This is viewed as vital to alleviate the strain of the illness for patients and to halt the transmission of highly drug-resistant gonorrhoea around the world.